Studying bowel scarring in ulcerative colitis with filgotinib
Part of Digestive system clinical trials.
This trial tests if filgotinib can help reduce intestinal scarring in people with active ulcerative colitis. It aims to understand fibrosis and find better ways to monitor treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (and if male, at least 30; if female, at least 40).
- You have an official diagnosis of ulcerative colitis.
- You have active disease seen during a colonoscopy (Mayo score 2 or higher).
- You are about to start treatment with filgotinib (a type of medication called a JAK inhibitor).
- You have either a thickened bowel wall on ultrasound OR higher than normal inflammation markers (CRP or calprotectin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special fluorescent versions of adalimumab and risankizumab to see inflammation in the bowel during an endoscopic procedure. It may help find out which treatment works best for each person's inflammation.
This study compares four newer biologic medications (infliximab, filgotinib, vedolizumab, and ustekinumab) to find which works best as a first biologic treatment for ulcerative colitis that hasn't responded well to standard drugs. It aims to help doctors choose the right biologic for each patient.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This trial tests if filgotinib, a pill for adults with ulcerative colitis, works in children and teenagers. It may help those whose current treatments are not working well enough or cause side effects.
Hear when a new Fibroblast Activation Protein Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.